José Luis
Bello López
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (9)
2019
-
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group
British Journal of Haematology, Vol. 184, Núm. 5, pp. 797-807
-
Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population
British Journal of Haematology, Vol. 185, Núm. 3, pp. 480-491
2017
-
Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma
Blood
-
Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group
British Journal of Haematology, Vol. 178, Núm. 5, pp. 699-708
2014
-
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial
The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111
-
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: A phase II GELTAMO trial
British Journal of Haematology, Vol. 167, Núm. 3, pp. 327-336
-
Simplification of risk stratification for splenic marginal zone lymphoma: A point-based score for practical use
Leukemia and Lymphoma
2012
-
Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: Development and validation on 593 cases
British Journal of Haematology, Vol. 159, Núm. 2, pp. 164-171
1996
-
Splenectomy for poor graft function after allogeneic bone marrow transplantation in patients with chronic myeloid leukemia
Leukemia, Vol. 10, Núm. 10, pp. 1615-1618